论文部分内容阅读
胃癌是消化系统最常见的恶性肿瘤,居我国恶性肿瘤病死率的第一位。由于大多数病人在确诊时已属进展期,传统的手术及放化疗整体预后不佳。分子靶向治疗是近年来肿瘤治疗领域中的研究热点,已在胃癌治疗中显示出高效、低毒等特点。目前分子靶向药物在胃癌治疗中的研究进展主要包括:(1)靶向于ErbB通道的胃癌靶向治疗;(2)以血管内皮生长因子及其受体为靶点的靶向治疗;(3)细胞周期调节剂与细胞凋亡促进剂;(4)针对上皮细胞黏附分子及胰岛素样生长因子-1受体的靶向治疗。
Gastric cancer is the most common malignant tumor of the digestive system, ranking first in the mortality of malignant tumors in China. As most patients are advanced at the time of diagnosis, the overall prognosis of traditional surgery and radiotherapy and chemotherapy is poor. Molecular targeted therapy is a research hotspot in the field of cancer therapy in recent years, which has shown the characteristics of high efficiency and low toxicity in the treatment of gastric cancer. At present, the research progress of molecular targeted drugs in the treatment of gastric cancer mainly includes: (1) targeted therapy of gastric cancer targeted to ErbB channel; (2) targeted therapy targeting vascular endothelial growth factor and its receptor; ( 3) cell cycle regulators and apoptosis promoters; and (4) targeted therapies targeting epithelial cell adhesion molecules and insulin-like growth factor-1 receptors.